Veracyte Q2 EPS $(0.12) Beats $(0.14) Estimate, Sales $90.32M Beat $74.66M Estimate
Portfolio Pulse from saritha@benzinga.com
Veracyte (NASDAQ:VCYT) reported Q2 losses of $(0.12) per share, beating the analyst consensus estimate of $(0.14) by 14.29%. This is a 7.69% increase over losses from the same period last year. The company also reported quarterly sales of $90.32 million, beating the analyst consensus estimate of $74.66 million by 20.98%, a 23.96% increase over sales from the same period last year.
August 08, 2023 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Veracyte's Q2 results exceeded expectations with a smaller loss and higher sales than estimated. This could potentially lead to a positive market reaction.
Veracyte's Q2 results exceeded analyst estimates, with a smaller loss per share and higher sales. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100